Referências

1. Tirkes T., Sandrasegaran K., Patel A.A., Hollar M.A., Tejada J.G., Tann M., Et al., Peritoneal and retroperitoneal anatomy and its relevance for cross-sectional imaging, Radiographics, 32, 451, pp. 437-452, (2012)
2. Goenka A.H., Shah S.N., Remer E.M., Imaging of the retroperitoneum, Radiol Clin N Am, 50, 2, pp. 333-355, (2012)
3. Coffin A., Boulay-Coletta I., Sebbag-Sfez D., Zins M., Radioanatomy of the retroperitoneal space, Diagn Interv Imaging, 96, 2, pp. 171-186, (2015)
4. Storm F.K., Eilber F.R., Mirra J., Morton D.L., Retroperitoneal sarcomas: A reappraisal of treatment, J Surg Oncol, 17, 1, pp. 1-7, (1981)
5. Storm F.K., Mahvi D.M., Diagnosis and management of retroperitoneal soft-tissue sarcoma, Ann Surg, 214, 1, pp. 2-10, (1991)
6. Merran S., Tumeurs rétropéritonéales primitives de l’adulte, J Radiol, 85, 2, pp. 252-264, (2004)
7. Ma G.L., Murphy J.D., Martinez M.E., Sicklick J.K., Epidemiology of gastrointestinal stromal tumors in the era of histology codes: Results of a population-based study, Cancer Epidemiol Biomark Prev, 24, 1, pp. 298-302, (2015)
8. Miettinen M., Monihan J.M., Sarlomo-Rikala M., Kovatich A.J., Carr N.J., Emory T.S., Et al., Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery, Am J Surg Pathol, 23, 9, (1999)
9. Miettinen M., Lasota J., Gastrointestinal stromal tumors -definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis, Virchows Arch, 438, 1, pp. 1-12, (2001)
10. Parab T.M., DeRogatis M.J., Boaz A.M., Grasso S.A., Issack P.S., Duarte D.A., Et al., Gastrointestinal stromal tumors: A comprehensive review, J Gastrointest Oncol, 10, 1, pp. 144-154, (2019)
11. Fletcher C.D.M., Berman J.J., Corless C., Gorstein F., Lasota J., Longley B.J., Et al., Diagnosis of gastrointestinal stromal tumors: A consensus approach, Int J Surg Pathol, 10, 2, pp. 81-89, (2002)
12. Yamamoto H., Oda Y., Kawaguchi K.-I., Nakamura N., Takahira T., Tamiya S., Saito T., Oshiro Y., Ohta Y., Yao T., Tsuneyoshi T., c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue), Am J Surg Pathol, 28, 4, pp. 479-488, (2004)
13. Sircar K., Hewlett B.R., Huizinga J.D., Chorneyko K., Berezin I., Riddell R.H., Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors, Am J Surg Pathol, 23, 4, pp. 377-389, (1999)
14. Miettinen M., Fetsch J.F., Sobin L.H., Lasota J., Gastrointestinal stromal tumors in patients with neurofibromatosis 1: A clinicopathologic and molecular genetic study of 45 cases, Am J Surg Pathol, 30, 1, pp. 90-96, (2006)
15. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., Et al., KIT activation is a ubiquitous feature of gastrointestinal stromal tumors, Cancer Res, 61, 22, pp. 8118-8121, (2001)
16. Rubin B.P., Fletcher J.A., Fletcher C.D.M., Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors, Int J Surg Pathol, 8, 1, pp. 5-10, (2000)
17. Hirota S., Isozaki K., Moriyama Y., Hashimoto H., Nishida T., Ishiguro S., Et al., Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 279, 5350, pp. 577-580, (1998)
18. Heinrich M.C., PDGFRA activating mutations in gastrointestinal stromal tumors, Science, 299, 5607, pp. 708-710, (2003)
19. Miettinen M., Wang Z.F., Lasota J., DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: A study of 1840 cases, Am J Surg Pathol, 33, 9, pp. 1401-1408, (2009)
20. Novelli M., Rossi S., Rodriguez-Justo M., Taniere P., Seddon B., Toffolatti L., Et al., DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours, Histopathology, 57, 2, pp. 259-270, (2010)
21. Ghanem N., Altehoefer C., Furtwangler A., Winterer J., Schafer O., Springer O., Et al., Computed tomography in gastrointestinal stromal tumors, Eur Radiol, 13, 7, pp. 1669-1678, (2003)
22. Miettinen M., Lasota J., Gastrointestinal stromal tumors: Pathology and prognosis at different sites, Semin Diagn Pathol, 23, 2, pp. 70-83, (2006)
23. Joensuu H., Vehtari A., Riihimaki J., Nishida T., Steigen S.E., Brabec P., Et al., Risk of recurrence of gastrointestinal stromal tumour after surgery: An analysis of pooled population-based cohorts, Lancet Oncol, 13, 3, pp. 265-274, (2012)
24. Giuliano K., Nagarajan N., Canner J., Najafian A., Wolfgang C., Schneider E., Et al., Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?, J Surg Oncol, 115, 3, pp. 351-357, (2017)
25. Lanke G., Lee J.H., How best to manage gastrointestinal stromal tumor, World J Clin Oncol, 8, 2, pp. 135-144, (2017)
26. Balachandran V.P., DeMatteo R.P., Gastrointestinal stromal tumors: Who should get imatinib and for how long?, Adv Surg, 48, pp. 165-183, (2014)
27. DeMatteo R.P., Ballman K.V., Antonescu C.R., Corless C., Kolesnikova V., Von Mehren M., Et al., Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial, Ann Surg, 258, 3, pp. 422-428, (2013)
28. DeMatteo R.P., Maki R.G., Singer S., Gonen M., Brennan M.F., Antonescu C.R., Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor, Ann Surg, 245, 3, pp. 347-352, (2007)
29. Verweij J., Casali P.G., Zalcberg J., LeCesne A., Reichardt P., Blay J.Y., Et al., Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial, Lancet, 364, 9440, pp. 1127-1134, (2004)
30. Joensuu H., Risk stratification of patients diagnosed with gastrointestinal stromal tumor, Hum Pathol, 39, 10, pp. 1411-1419, (2008)
31. Lee S.H., Ha H.K., Byun J.Y., Kim A.Y., Cho K.S., Lee Y.R., Et al., Radiological features of leiomyomatous tumors of the colon and rectum, J Comput Assist Tomogr, 24, 3, pp. 407-412, (2000)
32. Chun H.J., Byun J.Y., Chun K.A., Rha S.E., Jung S.E., Lee J.M., Et al., Gastrointestinal leiomyoma and leiomyosarcoma: CT differentiation, J Comput Assist Tomogr, 22, 1, pp. 69-74, (1998)
33. Trope C.G., Abeler V.M., Kristensen G.B., Diagnosis and treatment of sarcoma of the uterus. A review, Acta Oncol, 51, 6, pp. 694-705, (2012)
34. Juhasz-Boss I., Gabriel L., Bohle R.M., Horn L.C., Solomayer E.F., Breitbach G.P., Uterine leiomyosarcoma, Oncol Res Treat, 41, 11, pp. 680-686, (2018)
35. Romagnolo C., Leon A.E., Fabricio A.S.C., Taborelli M., Polesel J., Del Pup L., Et al., HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study, Gynecol Oncol, 141, 2, pp. 303-311, (2016)
36. Campos C., Sarian L.O., Jales R.M., Hartman C., Araujo K.G., Pitta D., Et al., Performance of the risk of malignancy index for discriminating malignant tumors in women with adnexal masses, J Ultrasound Med, 35, 1, pp. 143-152, (2016)
37. Timmerman D., Testa A.C., Bourne T., Ameye L., Jurkovic D., Van Holsbeke C., Et al., Simple ultrasound-based rules for the diagnosis of ovarian cancer, Ultrasound Obstet Gynecol, 31, 6, pp. 681-690, (2008)
38. Yanaranop M., Tiyayon J., Siricharoenthai S., Nakrangsee S., Thinkhamrop B., Rajavithi-ovarian cancer predictive score (R-OPS): A new scoring system for predicting ovarian malignancy in women presenting with a pelvic mass, Gynecol Oncol, 141, 3, pp. 479-484, (2016)
39. Kubecek O., Laco J., Spacek J., Petera J., Kopecky J., Kubeckova A., Et al., The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: A comprehensive review, Clin Exp Metastasis, 34, 5, pp. 295-307, (2017)
40. Bennett J.A., Oliva E., Pathology of the adnexal mass, Clin Obstet Gynecol, 58, 1, pp. 3-27, (2015)
41. Al-Agha O.M., Nicastri A.D., An in-depth look at Krukemberg tumor: An overview, Arch Pathol Lab Med, 130, 11, pp. 1725-1730, (2006)
42. Agnes A., Biondi A., Ricci R., Gallotta V., D'Ugo D., Persiani R., Krukenberg tumors: Seed, route and soil, Surg Oncol, 26, 4, pp. 438-445, (2017)
43. Bal A., Joshi K., Vaiphel K., Wig J.D., Primary duodenal neoplasms: A restrospective clinico-pathological analysis, World J Gastroenterol, 13, 7, pp. 1108-1111, (2007)
44. Barral M., Faraoun S.A., Fishman E.K., Dohan A., Pozzessere C., Berthelin M.A., Et al., Imaging features of rare pancreatic tumors, Diagn Interv Imaging, 97, 12, pp. 1259-1273, (2016)
45. Park J.J., Park B.K., Kim C.K., Adrenal imaging for adenoma characterization: Imaging features, diagnostic accuracies and differential diagnoses, Br J Radiol, 89, 1062, pp. 1-13, (2016)
46. Weston M.J., Virtual special issue: Renal masses, Clin Radiol, 72, 10, pp. 826-827, (2017)
47. Pilavaki M., Chourmouzi D., Kiziridou A., Skordalaki A., Zarampoukas T., Drevelengas A., Imaging of peripheral nerve sheath tumors with pathologic correlation: Pictorial review, Eur J Radiol, 52, 3, pp. 229-239, (2004)
48. Golan J.D., Jacques L., Nonneoplastic peripheral nerve tumors, Neurosurg Clin N Am, 15, 2, pp. 223-230, (2004)
49. Krutman M., Nishinari K., Pignataro B.S., Yazbek G., Zottele Bomfim G.A., Cavalcante R.N., Et al., Twenty years of experience in vascular reconstructions associated with resection of malignant neoplasms in a single cancer center, J Vasc Surg, 69, 6, pp. 1880-1888, (2019)
50. Modha A., Paty P., Bilsky M.H., Presacral ganglioneuromas, J Neurosurg Spine, 2, 3, pp. 366-371, (2009)
51. Skovronsky D.M., Oberholtzer J.C., Pathologic classification of peripheral nerve tumors, Neurosurg Clin N Am, 15, 2, pp. 157-166, (2004)
52. Neumann H.P.H., Young W.F., Eng C., Pheochromocytoma and paraganglioma, N Engl J Med, 381, 6, pp. 552-565, (2019)
53. Erickson D., Kudva Y.C., Ebersold M.J., Thompson G.B., Grant C.S., Van Heerden J.A., Et al., Benign paragangliomas: Clinical presentation and treatment outcomes in 236 patients, J Clin Endocrinol Metab, 86, 11, pp. 5210-5216, (2001)
54. Lee J.H., Barich F., Karnell L.H., Robinson R.A., Zhen W.K., Gantz B.J., Et al., National cancer data base report on malignant paragangliomas of the head and neck, Cancer, 94, 3, pp. 730-737, (2002)
55. Boedeker C.C., Neumann H.P.H., Maier W., Bausch B., Schipper J., Ridder G.J., Malignant head and neck paragangliomas in SDHB mutation carriers, Otolaryngol Head Neck Surg, 137, 1, pp. 126-129, (2007)
56. Elder E.E., Elder G., Larsson C., Pheochromocytoma and functional paraganglioma syndrome:No longer the 10% tumor, J Surg Oncol, 89, 3, pp. 193-201, (2005)
57. Parenti G., Zampetti B., Rapizzi E., Ercolino T., Giach V., Mannelli M., Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma, J Oncol, 2012, (2012)
58. Pacak K., Eisenhofer G., Ahlman H., Bornstein S.R., Gimenez-Roqueplo A.P., Grossman A.B., Et al., Pheochromocytoma: Recommendations for clinical practice from the First International Symposium, Nat Clin Pract Endocrinol Metab, 3, 2, pp. 92-102, (2007)
59. Welander J., Soderkvist P., Gimm O., Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas, Endocr Relat Cancer, 18, 6, pp. 253-276, (2011)
60. Eisenhofer G., Tischler A.S., De Krijger R.R., Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: From routine laboratory methods to disease stratification, Endocr Pathol, 23, 1, pp. 4-14, (2012)
61. Lenders J.W.M., Duh Q.Y., Eisenhofer G., Gimenez-Roqueplo A.P., Grebe S.K.G., Murad M.H., Et al., Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline, J Clin Endocrinol Metab, 99, 6, pp. 1915-1942, (2014)
62. Kliewer K.E., Wen D.R., Cancilla P.A., Cochran A.J., Paragangliomas: Assessment of prognosis by histologic, immunohistochemical, and ultrastructural techniques, Hum Pathol, 20, 1, pp. 29-39, (1989)
63. Plouin P.F., Gimenez-Roqueplo A.P., La Batide Alanore A., Salenave S., Duclos J.M., Evolving concepts in the diagnosis, prognosis, and treatment of pheochromocytoma, Rev Med Interne, 21, 12, pp. 1075-1085, (2000)
64. Lenders J.W.M., Pacak K., Walther M.M., Linehan W.M., Mannelli M., Friberg P., Et al., Biochemical diagnosis of pheochromocytoma, JAMA, 287, 11, pp. 1427-1434, (2002)
65. Davidson F.D., Phaeochromocytoma with normal urinary catecholamines: The potential value of urinary free metadrenalines, Ann Clin Biochem, 39, 6, pp. 557-566, (2002)
66. Garg P.K., Jain B.K., Kumar A., Bhatt S., Vibhav V., Fat poor angiomyolipoma with lymphadenopathy:Diagnostic dilemma, Urol Ann, 4, 2, pp. 126-129, (2012)
67. Sharma G., Jain A., Sharma P., Sharma S., Rathi V., Garg P.K., Giant exophytic renal angiomyolipoma masquerading as a retroperitoneal liposarcoma: A case report and review of literature, World J Clin Oncol, 9, 7, pp. 162-166, (2018)
68. Jinzaki M., Silverman S.G., Akita H., Mikami S., Oya M., Diagnosis of renal angiomyolipomas:Classic, fat-poor, and epithelioid types, Semin Ultrasound CT MR, 38, 1, pp. 37-46, (2017)
69. Tsai H.Y., Lee K.H., Ng K.F., Kao Y.T., Chuang C.K., Clinicopathologic analysis of renal epithelioid angiomyolipoma: Consecutively excised 23 cases, Kaohsiung J Med Sci, 35, 1, pp. 33-38, (2019)
70. Luna N.T., Mosquera J.E., Comba I.Y., Kinaan M., Otoya J., A primary adrenal epithelioid angiomyolipoma (PEComa) in a patient with tuberous sclerosis complex: Report of a case and review of the literature, Case Rep Med, 2020, pp. 4-7, (2020)
71. Redkar N., Patil M.A., Dhakate T., Kolhe P., Tuberous sclerosis complex presenting as bilateral large renal angiomyolipomas, BMJ Case Rep, 2012, pp. 1-4, (2012)
72. Shankar S., Hulikanthimatt K.S., Awatti S.M., Narayanrao S.T., Bilateral multifocal renal angiomyolipoma associated with Wunderlich’s syndrome in a tuberous sclerosis patient, J Clin Diagn Res, 9, 8, pp. ED01-ED03, (2015)
73. Kebria M., Black D., Borelli C., Modica I., Hensley M., Chi D.S., Primary retroperitoneal lymphangioleiomyomatosis in a postmenopausal woman: A case report and review of the literature, Int J Gynecol Cancer, 17, 2, pp. 528-532, (2007)
74. Slodkowska J., Patera J., Breborowicz J., Jarzemska A., Korzeniewska-Kosela M., Siemiatkowska K., Et al., Extrapulmonary lymphangioleiomyomatosis presented as the asymptomatic retroperitoneal tumours--two cases report, Pol J Pathol, 57, 4, pp. 205-207, (2006)
75. Sandrini A., Silverstone E., Yates D.H., Menstrual cycle variation of retroperitoneal lymphangioleiomyomas in lymphangioleiomyomatosis, Intern Med J, 41, 12, pp. 832-835, (2011)
76. Derweduwen A.M., Verbeken E., Stas M., Verschakelen J., Coolen J., Verleden G., Et al., Extrapulmonary lymphangioleiomyomatosis: A wolf in sheep’s clothing, Thorax, 68, 1, pp. 111-113, (2013)
77. Avila N.A., Bechtle J., Dwyer A.J., Ferrans V.J., Moss J., Lymphangioleiomyomatosis: CT of diurnal variation of lymphangioleiomyomas, Radiology, 221, 2, pp. 415-421, (2001)
78. Tobino K., Johkoh T., Fujimoto K., Sakai F., Arakawa H., Kurihara M., Et al., Computed tomographic features of lymphangioleiomyomatosis: Evaluation in 138 patients, Eur J Radiol, 84, 3, pp. 534-541, (2015)
79. Terada T., Giant fibrolipoma of the spermatic cord: Short communication, Pathol Int, 60, 4, pp. 330-332, (2010)
80. Weniger M., D'Haese J.G., Kunz W., Pratschke S., Guba M., Werner J., Et al., En-bloc resection of a giant retroperitoneal lipoma: A case report and review of the literature, BMC Res Notes, 8, 1, pp. 8-11, (2015)
81. Pisters P.W.T., O'Sullivan B., Retroperitoneal sarcomas: Combined modality treatment approaches, Curr Opin Oncol, 14, 4, pp. 400-405, (2002)
82. Stoeckle E., Coindre J.-M., Bonvalot S., Kantor G., Terrier P., Bonichon F., Et al., Prognostic factors in retroperitoneal sarcoma, Cancer, 92, 2, pp. 359-368, (2001)
83. Renne S.L., Iwenofu O.H., Pathology of retroperitoneal sarcomas: A brief review, J Surg Oncol, 117, 1, pp. 12-24, (2018)
84. Pham T.H., Iqbal C.W., Zarroug A.E., Donohue J.H., Moir C., Retroperitoneal sarcomas in children:Outcomes from an institution, J Pediatr Surg, 42, 5, pp. 829-833, (2007)
85. Marino-Enriquez A., Fletcher C.D.M., Cin P.D., Hornick J.L., Dedifferentiated liposarcoma with “homologous” lipoblastic (pleomorphic liposarcoma-like) differentiation: Clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria, Am J Surg Pathol, 34, 8, pp. 1122-1131, (2010)
86. Singer S., Antonescu C.R., Riedel E., Brennan M.F., Pollock R.E., Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma, Ann Surg, 238, 3, pp. 358-371, (2003)
87. Lahat G., Tuvin D., Wei C., Anaya D.A., Bekele B.N., Lazar A.J., Et al., New perspectives for staging and prognosis in soft tissue sarcoma, Ann Surg Oncol, 15, 10, pp. 2739-2748, (2008)
88. Alldinger I., Yang Q., Pilarsky C., Saeger H.D., Knoefel W.T., Peiper M., Retroperitoneal soft tissue sarcomas: Prognosis and treatment of primary and recurrent disease in 117 patients, Anticancer Res, 26, pp. 1577-1581, (2006)
89. Lewis J.J., Leung D., Woodruff J.M., Brennan M.F., Retroperitoneal soft-tissue sarcoma: Analysis of 500 patients treated and followed at a single institution, Ann Surg, 228, 3, pp. 355-365, (1998)
90. Anaya D.A., Lev D.C., Pollock R.E., The role of surgical margin status in retroperitoneal sarcoma, J Surg Oncol, 98, 8, pp. 607-610, (2008)
91. Toulmonde M., Bonvalot S., Meeus P., Stoeckle E., Riou O., Isambert N., Et al., Retroperitoneal sarcomas: Patterns of care at diagnosis, prognostic factors and focus on main histological subtypes:A multicenter analysis of the French Sarcoma Group, Ann Oncol, 25, 3, pp. 735-742, (2014)
92. van Houdt W.J., Raut C.P., Bonvalot S., Swallow C.J., Haas R., Gronchi A., New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: Making progress through collaboration, Curr Opin Oncol, 31, 4, pp. 310-316, (2019)
93. Ronchi A., Cozzolino I., Zito Marino F., Accardo M., Montella M., Panarese I., Et al., Extrapleural solitary fibrous tumor: A distinct entity from pleural solitary fibrous tumor. An update on clinical, molecular and diagnostic features, Ann Diagn Pathol, 34, pp. 142-150, (2018)
94. Gold J.S., Antonescu C.R., Hajdu C., Ferrone C.R., Hussain M., Lewis J.J., Et al., Clinicopathologic correlates of solitary fibrous tumors, Cancer, 94, 4, pp. 1057-1068, (2002)
95. Demicco E.G., Park M.S., Araujo D.M., Fox P.S., Bassett R.L., Pollock R.E., Et al., Solitary fibrous tumor: A clinicopathological study of 110 cases and proposed risk assessment model, Mod Pathol, 25, 9, pp. 1298-1306, (2012)
96. Mosquera J.M., Fletcher C.D.M., Expanding the spectrum of malignant progression in solitary fibrous tumors: A study of 8 cases with a discrete anaplastic component-is this dedifferentiated SFT?, Am J Surg Pathol, 33, 9, pp. 1314-1321, (2009)
97. Lee J.C., Fletcher C.D.M., Malignant fat-forming solitary fibrous tumor (so-called “lipomatous hemangiopericytoma”): Clinicopathologic analysis of 14 cases, Am J Surg Pathol, 35, 8, pp. 1177-1185, (2011)
98. Baldi G.G., Stacchiotti S., Mauro V., Dei Tos A.P., Gronchi A., Pastorino U., Et al., Solitary fibrous tumor of all sites: Outcome of late recurrences in 14 patients, Clin Sarcoma Res, 3, 1, (2013)
99. Gholami S., Cassidy M.R., Kirane A., Kuk D., Zanchelli B., Antonescu C.R., Et al., Size and location are the most important risk factors for malignant behavior in resected solitary fibrous tumors, Ann Surg Oncol, 24, 13, pp. 3865-3871, (2017)
100. Tay C.K.J., Teoh H.L., Su S., A common problem in the elderly with an uncommon cause: Hypoglycaemia secondary to the Doege-Potter syndrome, BMJ Case Rep, 2015, pp. 1-5, (2015)
101. Chmielecki J., Crago A.M., Rosenberg M., O'Connor R., Walker S.R., Ambrogio L., Et al., Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors, Nat Genet, 45, 2, pp. 131-132, (2013)
102. Doyle L.A., Vivero M., Fletcher C.D.M., Mertens F., Hornick J.L., Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics, Mod Pathol, 27, 3, pp. 390-395, (2014)
103. Cardillo G., Lococo F., Carleo F., Martelli M., Solitary fibrous tumors of the pleura, Curr Opin Pulm Med, 18, 4, pp. 339-346, (2012)
104. Park M.S., Patel S.R., Ludwig J.A., Trent J.C., Conrad C.A., Lazar A.J., Et al., Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor, Cancer, 117, 21, pp. 4939-4947, (2011)
105. Stacchiotti S., Negri T., Libertini M., Palassini E., Marrari A., De Troia B., Et al., Sunitinib malate in solitary fibrous tumor (SFT), Ann Oncol, 23, 12, pp. 3171-3179, (2012)
106. Valentin T., Fournier C., Penel N., Bompas E., Chaigneau L., Isambert N., Et al., Sorafenib in patients with progressive malignant solitary fibrous tumors: A subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO), Investig New Drugs, 31, 6, pp. 1626-1627, (2013)
107. Stacchiotti S., Simeone N., Lo Vullo S., Morosi C., Greco F.G., Gronchi A., Et al., Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study, Eur J Cancer, 106, pp. 225-233, (2019)
108. Grier H.E., Ewing’s sarcoma and primitive neuroectodermal tumors, Pediatr Clin N Am, 44, 4, pp. 991-1004, (1997)
109. Patnaik S., Yarlagadda J., Susarla R., Imaging features of Ewing’s sarcoma: Special reference to uncommon features and rare sites of presentation, J Cancer Res Ther, 14, 5, (2018)
110. Cash T., McIlvaine E., Krailo M.D., Lessnick S.L., Lawlor E.R., Laack N., Et al., Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children’s Oncology Group, Pediatr Blood Cancer, 63, 10, pp. 1771-1779, (2016)
111. Thompson L.D.R., Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases, Am J Surg Pathol, 26, 5, pp. 551-566, (2002)
112. Strong V.E., Kennedy T., Al-Ahmadie H., Tang L., Coleman J., Fong Y., Et al., Prognostic indicators of malignancy in adrenal pheochromocytomas: Clinical, histopathologic, and cell cycle/apoptosis gene expression analysis, Surgery, 143, 6, pp. 759-768, (2008)
113. Adjalle R., Plouin P.F., Pacak K., Lehnert H., Treatment of malignant pheochromocytoma, Horm Metab Res, 41, 9, pp. 687-696, (2009)
114. Li M.L., Fitzgerald P.A., Price D.C., Norton J.A., Iatrogenic pheochromocytomatosis: A previously unreported result of laparoscopic adrenalectomy, Surgery, 130, 6, pp. 1072-1077, (2001)
115. Bohle A., Studer U.E., Sonntag R.W., Scheidegger J.R., Primary or secondary extragonadal germ cell tumors?, J Urol, 135, 5, pp. 939-943, (1986)
116. Comiter C.V., Renshaw A.A., Benson C.B., Loughlin K.R., Burned-out primary testicular cancer:Sonographic and pathological characteristics, J Urol, 156, 1, pp. 85-88, (1996)
117. Richie J.P., Spontaneous regression of testicular germ cell tumors: An analysis of 42 cases. Balzer BL, Ulbright TM, Department of Pathology, Stanford University Hospital and Clinics, Stanford, CA, Urol Oncol, 25, 2, (2007)
118. Bokemeyer C., Nichols C.R., Droz J.P., Schmoll H.J., Horwich A., Gerl A., Et al., Extragonadal germ cell tumors of the mediastinum and retroperitoneum: Results from an international analysis, J Clin Oncol, 20, 7, pp. 1864-1873, (2002)
119. McAleer J.J.A., Nicholls J., Horwich A., Does extragonadal presentation impart a worse prognosis to abdominal germ-cell tumours?, Eur J Cancer, 28, 4-5, pp. 825-828, (1992)
120. Rajiah P., Sinha R., Cuevas C., Dubinsky T.J., Bush W.H., Kolokythas O., Imaging of uncommon retroperitoneal masses, Radiographics, 31, 4, pp. 949-976, (2011)
121. Tasu J.-P., Faye N., Eschwege P., Rocher L., Blery M., Imaging of burned-out testis tumor, J Ultrasound Med, 22, 5, pp. 515-521, (2003)
122. Gatcombe H.G., Assikis V., Kooby D., Johnstone P.A.S., Primary retroperitoneal teratomas: A review of the literature, J Surg Oncol, 86, 2, pp. 107-113, (2004)
123. Church J.M., Mucosal ischemia caused by desmoid tumors in patients with familial adenomatous polyposis: Report of four cases, Dis Colon Rectum, 41, 5, pp. 661-663, (1998)
124. Carlson J.W., Fletcher C.D.M., Immunohistochemistry for β-catenin in the differential diagnosis of spindle cell lesions: Analysis of a series and review of the literature, Histopathology, 51, 4, pp. 509-514, (2007)
125. Aitken S.J., Presneau N., Kalimuthu S., Dileo P., Berisha F., Tirabosco R., Et al., Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses, Virchows Arch, 467, 2, pp. 203-210, (2015)
126. Fiore M., Rimareix F., Mariani L., Domont J., Collini P., Le Pechoux C., Et al., Desmoid-type fibromatosis: A front-line conservative approach to select patients for surgical treatment, Ann Surg Oncol, 16, 9, pp. 2587-2593, (2009)
127. Salas S., Dufresne A., Bui B., Blay J.Y., Terrier P., Ranchere-Vince D., Et al., Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors:A wait-and-see policy according to tumor presentation, J Clin Oncol, 29, 26, pp. 3553-3558, (2011)
128. Burtenshaw S.M., Cannell A.J., McAlister E.D., Siddique S., Kandel R., Blackstein M.E., Et al., Toward observation as first-line management in abdominal desmoid tumors, Ann Surg Oncol, 23, 7, pp. 2212-2219, (2016)
129. Arvanitis M.L., Jagelman D.G., Fazio V.W., Lavery I.C., McGannon E., Mortality in patients with familial adenomatous polyposis, Dis Colon Rectum, 33, 8, pp. 639-642, (1990)
130. Nieuwenhuis M.H., Mathus-Vliegen E.M., Baeten C.G., Nagengast F.M., Van Der Bijl J., Van Dalsen A.D., Et al., Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients, Br J Cancer, 104, 1, pp. 37-42, (2011)
131. Soravia C., Berk T., McLeod R.S., Cohen Z., Desmoid disease in patients with familial adenomatous polyposis, Dis Colon Rectum, 43, 3, pp. 363-369, (2000)
132. Guillem J.G., Wood W.C., Moley J.F., Berchuck A., Karlan B.Y., Mutch D.G., Et al., ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes, J Clin Oncol, 24, 28, pp. 4642-4660, (2006)
133. Bertagnolli M.M., Morgan J.A., Fletcher C.D.M., Raut C.P., Dileo P., Gill R.R., Et al., Multimodality treatment of mesenteric desmoid tumours, Eur J Cancer, 44, 16, pp. 2404-2410, (2008)
134. Vaglio A., Salvarani C., Buzio C., Retroperitoneal fibrosis, Lancet, 367, 9506, pp. 241-251, (2006)
135. Vaglio A., Palmisano A., Alberici F., Maggiore U., Ferretti S., Cobelli R., Et al., Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: An open-label randomised controlled trial, Lancet, 378, 9788, pp. 338-346, (2011)
136. Palmisano A., Maritati F., Vaglio A., Chronic periaortitis: An update, Curr Rheumatol Rep, 20, 12, (2018)
137. Maritati F., Rocco R., Buttini E.A., Marvisi C., Nicastro M., Urban M.L., Et al., Clinical and prognostic significance of serum IgG4 in chronic periaortitis. An analysis of 113 patients, Front Immunol, 10, pp. 1-10, (2019)
138. Zen Y., Onodera M., Inoue D., Kitao A., Matsui O., Nohara T., Et al., Retroperitoneal fibrosis:A clinicopathologic study with respect to immunoglobulin G4, Am J Surg Pathol, 33, 12, pp. 1833-1839, (2009)
139. Scheel P.J., Feeley N., Retroperitoneal fibrosis: The clinical, laboratory, and radiographic presentation, Medicine, 88, 4, pp. 202-207, (2009)
140. Palmisano A., Urban M.L., Corradi D., Cobelli R., Alberici F., Maritati F., Et al., Chronic periaortitis with thoracic aorta and epiaortic artery involvement: A systemic large vessel vasculitis?, Rheumatology, 54, 11, pp. 2004-2009, (2015)
141. Cavalli G., Guglielmi B., Berti A., Campochiaro C., Sabbadini M.G., Dagna L., The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: Comprehensive review of the literature and of 10 new cases, Ann Rheum Dis, 72, 10, pp. 1691-1695, (2013)
142. Milne P., Bigley V., Bacon C.M., Neel A., McGovern N., Bomken S., Et al., Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults, Blood, 130, 2, pp. 167-175, (2017)
143. Arnaud L., Gorochov G., Charlotte F., Lvovschi V., Parizot C., Larsen M., Et al., Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: A single-center series of 37 patients, Blood, 117, 10, pp. 2783-2790, (2011)
144. Serratrice J., Granel B., De Roux C., Pellissier J.F., Swiader L., Bartoli J.M., Et al., “Coated aorta”:A new sign of Erdheim-Chester disease, J Rheumatol, 27, 6, pp. 1550-1553, (2000)
145. Habermann T.M., Steensma D.P., Lymphadenopathy, Mayo Clin Proc, 75, 7, pp. 723-732, (2000)
146. Altieri A., Bermejo J.L., Hemminki K., Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: The Swedish Family-Cancer Database, Blood, 106, 2, pp. 668-672, (2005)
147. Smedby K.E., Hjalgrim H., Askling J., Chang E.T., Gregersen H., Porwit-MacDonald A., Et al., Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype, J Natl Cancer Inst, 98, 1, pp. 51-60, (2006)
148. Wang S.S., Slager S.L., Brennan P., Holly E.A., De Sanjose S., Bernstein L., Et al., Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): A pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph), Blood, 109, 8, pp. 3479-3488, (2007)
149. Clarke C.A., Morton L.M., Lynch C., Pfeiffer R.M., Hall E.C., Gibson T.M., Et al., Risk of lymphoma subtypes after solid organ transplantation in the United States, Br J Cancer, 109, 1, pp. 280-288, (2013)
150. Luo D., Zhou T., Tao Y., Feng Y., Shen X., Mei S., Exposure to organochlorine pesticides and non-Hodgkin lymphoma: A meta-analysis of observational studies, Sci Rep, 6, pp. 1-11, (2016)
151. Zhang Y., De Sanjose S., Bracci P.M., Morton L.M., Wang R., Brennan P., Et al., Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma, Am J Epidemiol, 167, 11, pp. 1321-1331, (2008)
152. Wang F., Xu R.H., Han B., Shi Y.X., Luo H.Y., Jiang W.Q., Et al., High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers, Cancer, 109, 7, pp. 1360-1364, (2007)
153. Fallah M., Liu X., Ji J., Forsti A., Sundquist K., Hemminki K., Autoimmune diseases associated with non-Hodgkin lymphoma: A nationwide cohort study, Ann Oncol, 25, 10, pp. 2025-2030, (2014)
154. Larsson S.C., Wolk A., Body mass index and risk of non-Hodgkin’s and Hodgkin’s lymphoma:A meta-analysis of prospective studies, Eur J Cancer, 47, 16, pp. 2422-2430, (2011)
155. Anderson T., Chabner B.A., Young R.C., Berard C.W., Garvin A.J., Simon R.M., Et al., Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute, Cancer, 50, 12, pp. 2699-2707, (1982)
156. Sriwatanawongsa V., Cardoso R., Chang P., Incidence of malignancy in peripheral lymph node biopsy, Am Surg, 51, 10, pp. 587-590, (1985)
157. Hehn S.T., Grogan T.M., Miller T.P., Utility of fine-needle aspiration as a diagnostic technique in lymphoma, J Clin Oncol, 22, 15, pp. 3046-3052, (2004)
158. Lachar W.A., Shahab I., Saad A.J., Accuracy and cost-effectiveness of core needle biopsy in the evaluation of suspected lymphoma: A study of 101 cases, Arch Pathol Lab Med, 131, 7, pp. 1033-1039, (2007)
159. Asoglu O., Porter L., Donohue J.H., Cha S.S., Laparoscopy for the definitive diagnosis of intra-abdominal lymphoma, Mayo Clin Proc, 80, 5, pp. 625-631, (2005)
160. Barrington S.F., Mikhaeel N.G., Kostakoglu L., Meignan M., Hutchings M., Mueller S.P., Et al., Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group, J Clin Oncol, 32, 27, pp. 3048-3058, (2014)
161. Choi S.M., O'Malley D.P., Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms, Ann Diagn Pathol, 37, pp. 67-74, (2018)
162. Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., Et al., Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification, J Clin Oncol, 32, 27, pp. 3059-3067, (2014)
163. Talat N., Belgaumkar A.P., Schulte K.M., Surgery in Castleman’s disease: A systematic review of 404 published cases, Ann Surg, 255, 4, pp. 677-684, (2012)
164. Yu L., Tu M., Cortes J., Xu-Monette Z.Y., Miranda R.N., Zhang J., Et al., Clinical and pathological characteristics of HIV-and HHV-8-negative Castleman disease, Blood, 129, 12, pp. 1658-1668, (2017)
165. Kishimoto T., IL-6: From its discovery to clinical applications, Int Immunol, 22, 5, pp. 347-352, (2010)
166. Murakami M., Johkoh T., Hayashi S., Ohshima S., Mizuki M., Nakatsuka S., Et al., Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan, Mod Rheumatol, 30, 5, pp. 843-851, (2020)